Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts

Key Points

• Consensus "Hold": Seventeen analysts cover Hims & Hers with a consensus Hold (1 sell, 13 hold, 3 buy) and an average 12‑month price target of $30.46.
• Novo Nordisk deal is material: A settlement and commercial partnership lets HIMS offer Wegovy/Ozempic on its platform, reducing legal risk and opening a potential high‑margin GLP‑1 revenue stream that has prompted analyst upgrades.
• Mixed fundamentals and risks: Q4 showed an EPS beat but a slight revenue miss, insiders have sold shares (about 80,463 over 90 days), and a securities‑style investigation plus high short interest create headline and volatility risk.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has been given a consensus rating of "Hold" by the seventeen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $30.4643.

A number of brokerages have recently weighed in on HIMS. BTIG Research cut shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research note on Tuesday, February 24th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Bank of America upgraded shares of Hims & Hers Health from an "underperform" rating to a "neutral" rating and lifted their target price for the stock from $12.50 to $23.00 in a report on Tuesday. Leerink Partners cut their target price on shares of Hims & Hers Health from $20.00 to $17.50 and set a "market perform" rating for the company in a research report on Tuesday, February 24th. Finally, TD Cowen decreased their price target on shares of Hims & Hers Health from $20.00 to $17.00 and set a "hold" rating for the company in a report on Tuesday, February 24th.

Insider Activity

In other news, CFO Oluyemi Okupe sold 9,067 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the sale, the chief financial officer directly owned 91,617 shares of the company's stock, valued at approximately $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm's stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the sale, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. The trade was a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 80,463 shares of company stock worth $2,846,696 over the last 90 days. Company insiders own 17.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. grew its position in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock worth $127,237,000 after purchasing an additional 2,128,587 shares during the last quarter. Norges Bank bought a new position in shares of Hims & Hers Health during the 4th quarter worth about $62,153,000. Clear Street LLC acquired a new position in shares of Hims & Hers Health during the second quarter valued at about $83,582,000. Finally, Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health during the third quarter valued at about $87,372,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $23.47 on Wednesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The firm has a market cap of $5.35 billion, a price-to-earnings ratio of 46.01, a P/E/G ratio of 4.24 and a beta of 2.55. The business's 50-day simple moving average is $24.31 and its 200-day simple moving average is $37.75. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company's revenue for the quarter was up 28.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.11 EPS. As a group, equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Settlement & commercial partnership with Novo Nordisk ends recent patent fight and lets HIMS offer FDA‑approved Wegovy/Ozempic (including new pill formats) on its platform — this materially reduces legal risk and opens a new, high‑margin revenue stream. Read More.
• Positive Sentiment: Multiple analyst upgrades and higher price targets followed the Novo news (Needham to Buy, Citi/Deutsche Bank raised targets/ratings), which supports further upside if GLP‑1 sales ramp. Read More.
• Positive Sentiment: HIMS is expanding its digital‑care platform (new specialties, lab testing, international moves) — a broader service set increases addressable market and cross‑sell opportunities for new branded drug offerings. Read More.
• Neutral Sentiment: Extremely high short interest and recent rapid gains raise the possibility of short‑squeeze‑driven volatility; that can amplify upside but also produce sharp reversals. Monitor short interest and volume closely. Read More.
• Neutral Sentiment: Recent Q4/FY results showed an EPS beat but a slight revenue miss — fundamentals show growth but remain mixed; GLP‑1 revenue could change near‑term guidance if rollout scales. Read More.
• Negative Sentiment: An asset manager has trimmed/left positions, signaling some institutional caution despite the deal — this could limit sustained buying if sentiment cools. Read More.
• Negative Sentiment: A securities‑style investigation into officers and directors was announced earlier this month — while the Novo settlement reduces one legal risk, governance/claims risk remains a headline risk for investors. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.